Christian Hampp

Regeneron Pharmaceuticals, Inc.

Poster(s):

• ((SLA-025)) (SLA-025) Second Primary Malignancy in Patients with Diffuse Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy and Other Systemic Anti-Cancer Therapy: A Real-World Evidence from a Large US National Claims Database
  Sunday, August 24, 2025

  12:15 PM - 1:15 PM ET

• ((SLB-022)) (SLB-022) Concordance between blinded independent central review committee and physician-assessed responses: Analyses based on a real-world external control arm in relapsed/refractory multiple myeloma using IMWG data
  Monday, August 25, 2025

  11:45 AM - 12:45 PM ET

• ((B-188)) (B-188) Safety and Effectiveness of Cemiplimab in Combination with Platinum-Doublet Chemotherapy by Demographic Characteristics in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: An Ongoing Real World Evidence Study
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• ((C-153)) (C-153) Mind the Gap: a literature review to assess definitions of treatment discontinuation in oncology studies
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• ((C-207)) (C-207) Implementing robust machine learning pipelines with real-world data: identifying predictors of immune mediated adverse events among patients with advanced melanoma treated with immune checkpoint inhibitors
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• ((C-211)) (C-211) Immune-mediated adverse events in patients with high-risk melanoma receiving immune checkpoint inhibitors in adjuvant and first-line treatment settings: a real-world analysis
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• ((C-214)) (C-214) Second Primary Malignancy in Patients with Multiple Myeloma Receiving Chimeric Antigen Receptor T-Cell Therapy and Other Systemic Anticancer Therapy: A Comparative Study Using a Real-World Database
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET